Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year High - Time to Buy?

Key Points

• Urogen Pharma reached a new 52-week high of $19.89, experiencing positive trading momentum with a current trading price of $19.32.
• Analysts generally have a positive outlook on the stock, with an average target price of $32.86 and several "buy" ratings issued by brokerages, including a recent upgrade to $30.00 from Guggenheim.
• Despite strong analyst ratings, Urogen Pharma reported a loss of $0.92 earnings per share in its last quarterly report, missing estimates and indicating challenges in profitability.

Urogen Pharma (NASDAQ:URGN - Get Free Report) shares reached a new 52-week high during trading on Monday . The company traded as high as $19.89 and last traded at $19.32, with a volume of 1413 shares trading hands. The stock had previously closed at $19.40.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on URGN. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Urogen Pharma in a report on Tuesday, July 8th. Finally, Guggenheim reissued a "buy" rating and set a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.86.

Urogen Pharma Stock Down 5.0%

The business has a 50 day moving average of $13.17 and a 200 day moving average of $11.17. The company has a market capitalization of $878.03 million, a P/E ratio of -6.17 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.20). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. On average, research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider directly owned 153,378 shares of the company's stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel directly owned 41,492 shares in the company, valued at approximately $794,156.88. This trade represents a 15.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,833 shares of company stock valued at $280,567. Insiders own 4.70% of the company's stock.

Hedge Funds Weigh In On Urogen Pharma

Several hedge funds have recently bought and sold shares of the company. CWM LLC grew its holdings in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after buying an additional 5,140 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Urogen Pharma during the fourth quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in Urogen Pharma during the 4th quarter valued at about $67,000. GAMMA Investing LLC boosted its position in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Urogen Pharma in the 4th quarter valued at approximately $101,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.